Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Oncogenic ras alleles are among the most common mutations found in patients with acute myeloid leukemia (AML). Previously, the role of oncogenic ras in cancer was assessed in model systems overexpressing oncogenic ras from heterologous promoters. However, there is increasing evidence that subtle differences in gene dosage and regulation of gene expression from endogenous promoters play critical roles in cancer pathogenesis. We characterized the role of oncogenic K-ras expressed from its endogenous promoter in the hematopoietic system using a conditional allele and IFN-inducible, Cre-mediated recombination. Mice developed a completely penetrant myeloproliferative syndrome characterized by leukocytosis with normal maturation of myeloid lineage cells; myeloid hyperplasia in bone marrow; and extramedullary hematopoiesis in the spleen and liver. Flow cytometry confirmed the myeloproliferative phenotype. Genotypic and Western blot analysis demonstrated Cre-mediated excision and expression, respectively, of the oncogenic K-ras allele. Bone marrow cells formed growth factor-independent colonies in methylcellulose cultures, but the myeloproliferative disease was not transplantable into secondary recipients. Thus, oncogenic K-ras induces a myeloproliferative disorder but not AML, indicating that additional mutations are required for AML development. This model system will be useful for assessing the contribution of cooperating mutations in AML and testing ras inhibitors in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Expression of the most common KRAS mutation (G12D) in mouse hematopoietic cells causes a fatal myeloproliferative neoplasm (MPN).6,7”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 3×
“Myeloid progenitors were distinguished as Lin–Sca-1–c-Kit+CD34+FcγRII/IIIlo common myeloid progenitors (CMPs), Lin–Sca-1–cKit+CD34+FcγRII/IIIhi granulocyte-monocyte progenitors (GMPs), and Lin–Sca-1–c-Kit+CD34–FcγII/IIIlo megakaryocyte-erythrocyte progenitors (MEPs) (43).”
BackgroundSelf-citationAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 4×
“floxed LSL–K-ras G12D allele (38) containing a transcriptional ter-”
BackgroundResultInfluentialSelf-citationDaley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756 · cited 4×
“The Journal of Clinical Investigation | February 2004 | Volume 113 | Number 4 537 Growth factor–independent colony-forming activity of bone marrow cells has also been described in TEL-JAK2 and BCR/ABL murine bone marrow transplant models (51, 52).”
InfluentialInducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641 · cited 4×
“In studies of Mx1-Cre–mediated recombination of a floxed DNA polymerase β gene, pI-pC treatment yielded high recombination efficiencies in hematopoietic tissues (liver, 100%; spleen, 94%; and thymus, 40%) and lower levels in nonhematopoietic tissues such as heart, kidney, lung, and duodenum (37).”
BackgroundMethodInfluentialThe roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 1×
“Examples of tyrosine kinase gain-of-function mutations in AML include FLT3 activation loop point mutations, FLT3 juxtamembrane region internal tandem duplications (ITDs) (14), C-KIT point mutations (15), and the tyrosine kinase fusion products of chromosomal translocations such as TEL/ TRKC associated with t(12;15) (1…”
BackgroundSelf-citationSomatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 2×
“Papillomas and thymic lymphomas have been previously observed in 30% of adenovirus-Cre–treated oncogenic K-ras mice (40).”
BackgroundMethodSelf-citationSong, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100 · cited 2×
“KM – 8–83 (35) 34–53 (41) 156–885 (583) 70–1,271 (540) 704–2,777 (1491) MPD n = 6 n = 6 n = 6 n = 8 n = 8”
BackgroundSelf-citationRodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792 · cited 1×
“Transgenic mice expressing viral H-ras from the MMTV promoter/enhancer developed B cell lymphoblastic lymphomas at low frequency (34).”
Background
Cited by
Items 101–200 of 272
An unexpected new role of mutant Ras: perturbation of human embryonic development
Kratz, C. P., Niemeyer, C. M., & Zenker, M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0135-4 · Cited by 58
“In a murine model, somatic activation of K-Ras in hematopoietic cells initiates a rapidly fatal MPD modeling JMML [20, 21].”
BackgroundOtero, D. C., Baker, D. P., & David, M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203086 · Cited by 63
“Indeed, Mx-1 Cre was suggested to exhibit “leaky” expression (31, 33).”
BackgroundRole of cyclic AMP response element binding protein in human leukemias
Shankar, D. B., Cheng, J. C., & Sakamoto, K. M. (2005) · Cancer · doi:10.1002/cncr.21401 · Cited by 63
Chang, Y., You, X., Kong, G., Ranheim, E. A., Wang, J., Du, J., Liu, Y., Zhou, Y., Ryu, M.-J., & Zhang, J. (2015) · Leukemia · doi:10.1038/leu.2015.85 · Cited by 55
Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm
Kong, G., Wunderlich, M., Yang, D. T., Ranheim, E. A., Young, K. H., Wang, J., Chang, Y., Du, J., Liu, Y., Tey, S.-R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74182 · Cited by 52
“We tested this hypothesis in our NrasG12D/G12D model because unlike in KrasG12D/+ mice (8), 100% of NrasG12D/G12D mice die of severe JMML/MP-CMML without the complications of hyperplasia phenotypes in other tissues (12).”
Liu, W., Yu, W.-M., Zhang, J., Chan, R. J., Loh, M. L., Zhang, Z., Bunting, K. D., & Qu, C.-K. (2016) · Leukemia · doi:10.1038/leu.2016.326 · Cited by 51
Illmer, T., Thiede, C., Fredersdorf, A., Stadler, S., Neubauer, A., Ehninger, G., & Schaich, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2232 · Cited by 51
“It could be shown that these mutations account for phenotypic changes in transformed hematopoietic cells like hyperproliferation, hypersensitivity to growth factor stimulation, and IL-3– independent colony-forming unit activity (10, 11).”
BackgroundThe role of PKC and PDK1 in monocyte lineage specification by Ras
Pearn, L., Fisher, J., Burnett, A. K., & Darley, R. L. (2007) · Blood · doi:10.1182/blood-2006-09-047217 · Cited by 48
Khandanpour, C., Krongold, J., Schütte, J., Bouwman, F. C. M., Vaßen, L., Gaudreau, M., Chen, R., Calero‐Nieto, F. J., Diamanti, E., Hannah, R., et al. (2012) · Blood · doi:10.1182/blood-2011-02-334722 · Cited by 53
Robertson, A. L., Avagyan, S., Gansner, J. M., & Zon, L. I. (2016) · FEBS Letters · doi:10.1002/1873-3468.12415 · Cited by 45
Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
Gupta, A., Meena, J. P., Chopra, A., Tanwar, P., & Seth, R. K. (2021) · PubMed · Cited by 44
Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia
Zebisch, A., Wölfler, A., Fried, I., Wolf, O., Lind, K., Bodner, C., Haller, M., Drasche, A., Pirkebner, D., Matallanas, D., et al. (2012) · Leukemia · doi:10.1038/leu.2012.61 · Cited by 45
Kim, W.-I., Matise, I., Diers, M. D., & Largaespada, D. A. (2008) · Blood · doi:10.1182/blood-2008-01-132316 · Cited by 42
Kong, G., Chang, Y.-I., Damnernsawad, A., You, X., Du, J., Ranheim, E. A., Lee, W., Ryu, M.-J., Zhou, Y., Xing, Y., et al. (2016) · Leukemia · doi:10.1038/leu.2016.40 · Cited by 43
Wen, Z. H., Rajagopalan, A., Flietner, E. D., Yun, G., Chesi, M., Furumo, Q., Burns, R. T., Papadas, A., Ranheim, E. A., Pagenkopf, A. C., et al. (2020) · Blood · doi:10.1182/blood.2020007156 · Cited by 50
Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo
Braun, B. S., Archard, J. A., Ziffle, J. V., Tuveson, D. A., Jacks, T., & Shannon, K. (2006) · Blood · doi:10.1182/blood-2006-01-013490 · Cited by 41
Self-citationWelch, J. S., Yuan, W., & Ley, T. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42953 · Cited by 41
“(b) t(15;17) is a somatically acquired event, but all prior models have used constitutive PML-RARA expression, raising the possibility that hematopoietic cells may have adapted to tolerate PML-RARA expression during embryogenesis and/or early adult life.”
BackgroundResultInfluentialRunx3 in Immunity, Inflammation and Cancer
Lotem, J., Levanon, D., Negreanu, V., Bauer, O., Hantisteanu, S., Dicken, J., & Groner, Y. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_23 · Cited by 44
A most formidable arsenal: genetic technologies for building a better mouse
Clark, J. F., Dinsmore, C. J., & Soriano, P. M. (2020) · Genes & Development · doi:10.1101/gad.342089.120 · Cited by 45
“This strategy can be used to overexpress (or express mutant forms of) genes to study their function (Chan et al. 2004), mark cells with expression of LacZ or EGFP for lineage tracing or cell sorting (Soriano 1999; Abe and Fujimori 2013), exert optogenetic control over signaling (Deisseroth 2011),…”
BackgroundMyeloproliferative Neoplasm Animal Models
Mullally, A., Lane, S. W., Brumme, K., & Ebert, B. L. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.07.007 · Cited by 37
Forty years of cancer modelling in the mouse
Hirst, G. L., & Balmain, A. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.05.013 · Cited by 43
“Switch on/off systems to regulate gene expression include interferon, [31], tetracycline, which has been used widely to control numerous transgenes ([32], reviewed in [33]) and hormonally regulatable fusion constructs such as the myc-oestrogen receptor (mycER) system [34] which has been used to look at myc expression…”
BackgroundStirewalt, D. L., Pogosova‐Agadjanyan, E. L., Tsuchiya, K. D., Joaquin, J., & Meshinchi, S. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.27 · Cited by 38
Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia
Zwaan, C. M., & Kaspers, G. J. L. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05167.x · Cited by 38
“In mouse models FLT3/ITD, PDGFRb and RAS mutations induce myeloproliferative diseases, but they do not induce leukaemia (Kelly et al, 2002; Grisolano et al, 2003; Chan et al, 2004).”
BackgroundTargeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras
Akutagawa, J., Huang, T. Q., Epstein, I., Chang, T., Quirindongo-Crespo, M., Cottonham, C. L., Dail, M., Slusher, B. S., Friedman, L. S., Sampath, D., et al. (2016) · Leukemia · doi:10.1038/leu.2016.14 · Cited by 35
Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
Baum, K. J., & Ren, R. (2008) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-1-5 · Cited by 37
“It has been shown that both oncogenic Ras and STAT5 can induce myeloproliferative disease [32-34], yet adult hematopoiesis appears normal in STAT5A/B-deficient mice [35].”
BackgroundWild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice
Staffas, A., Karlsson, C., Persson, M., Palmqvist, L., & Bergö, M. O. (2014) · Leukemia · doi:10.1038/leu.2014.315 · Cited by 36
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease
Rau, R. E., Magoon, D., Greenblatt, S. M., Li, L., Annesley, C., Duffield, A. S., Huso, D. L., McIntyre, E., Clohessy, J. G., Reschke, M., et al. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.10.005 · Cited by 35
Updates on Old and Weary Haematopoiesis
Konieczny, J., & Arranz, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092567 · Cited by 42
Zhang, J., & Lodish, H. F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507446102 · Cited by 34
Archambeault, S., Flores, N. J., Yoshimi, A., Kratz, C. P., Reising, M., Fischer, A., Noellke, P., Locatelli, F., Sedláček, P., Flotho, C., et al. (2007) · Blood · doi:10.1182/blood-2007-06-093302 · Cited by 33
Oki, T., Kitaura, J., Watanabe‐Okochi, N., Nishimura, K., Maehara, A., Uchida, T., Komeno, Y., Nakahara, F., Harada, Y., Sonoki, T., et al. (2011) · Leukemia · doi:10.1038/leu.2011.328 · Cited by 32
Germeshausen, M., Schulze, H., Kratz, C. P., Wilkens, L., Repp, R., Shannon, K., Welte, K., & Ballmaier, M. (2005) · Leukemia · doi:10.1038/sj.leu.2403663 · Cited by 32
Meyer, M., Rübsamen, D., Slany, R. K., Illmer, T., Stabla, K., Roth, P., Stiewe, T., Eilers, M., & Neubauer, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007768 · Cited by 32
“Supporting this notion, oncogenic RAS alone induces a myeloproliferative state in murine models [8–12] and in cooperation with nuclear oncogenes such as PML-RARa induces acute leukemia [13].”
BackgroundJamalpour, M., Li, X., Gustafsson, K. U., Tyner, J. W., & Welsh, M. (2018) · Tumor Biology · doi:10.1177/1010428318771472 · Cited by 31
“The Kras2/Mx1-Cre (KM) mouse model has been used for triggering the expression of an oncogenic Kras in the bone marrow allowing the mice to develop T-cell leukemia and/or T-cell thymic lymphoma.(31,32) A combination of this oncogene with Shb deletion was used in order to investigate the effects of Shb deficiency on Kr…”
MethodSystemic activation of K-ras rapidly induces gastric hyperplasia and metaplasia in mice.
Matkar, S. S., Durham, A. C., Brice, A. K., Wang, T. C., Rustgi, A. K., & Hua, X. (2011) · PubMed · Cited by 36
Hepatic Temporal Gene Expression Profiling in Helicobacter hepaticus-Infected A/JCr Mice
Boutin, S. R., Rogers, A. B., Shen, Z., Fry, R. C., Love, J. A., Nambiar, P. R., Suerbaum, S., & Fox, J. G. (2004) · Toxicologic Pathology · doi:10.1080/01926230490524058 · Cited by 32
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo
Shieh, A., Ward, A. F., Donlan, K. L., Harding-Theobald, E. R., Xu, J., Mullighan, C. G., Zhang, C., Chen, S.-C., Su, X., Downing, J. R., et al. (2013) · Blood · doi:10.1182/blood-2012-05-432252 · Cited by 28
Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
Berg, J. L., Perfler, B., Hatzl, S., Mayer, M.-C., Wurm, S., Uhl, B., Reinisch, A., Klymiuk, I., Tierling, S., Pregartner, G., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-020-00979-2 · Cited by 29
Repressible transgenic model of NRAS oncogene–driven mast cell disease in the mouse
Wiesner, S. M., Jones, J. M., Hasz, D. E., & Largaespada, D. A. (2005) · Blood · doi:10.1182/blood-2004-08-3306 · Cited by 31
Kaushansky, K. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.11.005 · Cited by 29
Stieglitz, E., Lee, A. G., Angus, S. P., Davis, C. M., Barkauskas, D. A., Hall, D. C., Kogan, S. C., Meyer, J., Rhodes, S. D., Tasian, S. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1376 · Cited by 30
Morsia, E., Torre, E., Poloni, A., Olivieri, A., & Rupoli, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094573 · Cited by 31
“Furthermore, oncogenic K-ras induces a myeloproliferative disorder but AML, indicating that additional mutations are required [92].”
BackgroundHirouchi, T., Takabatake, T., Yoshida, K., Nitta, Y., Nakamura, M. M., Tanaka, S., Ichinohe, K., Oghiso, Y., & Tanaka, K. J. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.01.015 · Cited by 30
Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice
Cutts, B. A., Sjogren, A.-K. M., Andersson, K., Wahlstrom, A. M., Karlsson, C., Swolin, B., & Bergö, M. O. (2009) · Blood · doi:10.1182/blood-2009-02-205146 · Cited by 28
Fátrai, S., van Gosliga, D., Han, L., Daenen, S. M. G. J., Vellenga, E., & Schuringa, J. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.201848 · Cited by 28
Drosten, M., Simón-Carrasco, L., Hernández-Porras, I., Lechuga, C. G., Blasco, M. T., Jacob, H. K. C., Fabbiano, S., Potenza, N., Bustelo, X. R., Guerra, C. E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2925 · Cited by 30
“Barbacid), Castilla-Le on Autonomous Government (CSI101U13, BIO/SA01/15), the Spanish Ministry of Economy and Competitiveness (SAF2012-31371, RD12/0036/0002), Worldwide Cancer Research (14-1248), the Sol orzano Foundation, and the Ram on Areces Foundation (X.”
BackgroundConstitutive MAP Kinase Activation in Hematopoietic Stem Cells Induces a Myeloproliferative Disorder
Chung, E., Hsu, C.-L., & Kondo, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028350 · Cited by 27
“Lastly, the mixed MDS/MPN category, which was added in 2001, was specifically created to accommodate diseases such as juvenile myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML) [6].”
BackgroundResultInfluentialMouse models of K-ras-initiated carcinogenesis
Janssen, K., Abala, M., Marjou, F. E., Louvard, D., & Robine, S. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.07.004 · Cited by 35
Physiological Analysis of Oncogenic K‐Ras
Pérez-Mancera, P. A., & Tuveson, D. A. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)07053-9 · Cited by 28
Self-citationChronic myelomonocytic leukemia: Forefront of the field in 2015
Benton, C. B., Nazha, A., Pemmaraju, N., & Garcia‐Manero, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.03.002 · Cited by 32
“A number of mouse models that overexpress Nras or Kras in the hematopoietic compartment have been shown to develop CMML-like disease [87-89].”
BackgroundYoshimi, A., Kojima, S., & Hirano, N. (2009) · Pediatric Drugs · doi:10.2165/11316200-000000000-00000 · Cited by 26
“Recent mouse models of NF1-/-, KRASG12D andPTPN11D61G suggest that the deregulation of the RAS signaling pathway can initiate myeloproliferative diseases.([42-46]) However, it is not clear whether a mutation of only one of the PTPN11, RAS, or NF1 genes is sufficient to cause the development of JMML in humans.”
Wong, J. C. Y., Zhang, Y., Lieuw, K. H., Tran, M. T., Forgó, E., Weinfurtner, K. M., Alzamora, P., Kogan, S. C., Akagi, K., Wolff, L., et al. (2010) · Blood · doi:10.1182/blood-2009-07-232504 · Cited by 26
Zhang, J., Liu, Y., Beard, C., Tuveson, D. A., Jaenisch, R., Jacks, T., & Lodish, H. F. (2007) · Blood · doi:10.1182/blood-2006-09-047050 · Cited by 26
Self-citationMurine Models of Acute Myeloid Leukemia
Kurtz, K. J., Conneely, S. E., O'Keefe, M. B., Wohlan, K., & Rau, R. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.854973 · Cited by 29
Mechanisms of aneuploidy induction by RAS and RAF oncogenes.
Kamata, T., & Pritchard, C. A. (2011) · Europe PMC (PubMed Central) · Cited by 31
elhefni (2011) · OncoTargets and Therapy · doi:10.2147/ott.s12602 · Cited by 26
“In general, RAS mutations lead to a resistance of the RAS proteins to signaling provided by guanosine triphosphatase (GTPase)-activating proteins thus remaining locked in the active GTP-bound state.(1,2) This constitutive activity is furthermore translated via a cascade of key signaling events that contribute to the r…”
Thivakaran, A., Botezatu, L., Hönes, J. M., Schütte, J., Vaßen, L., Al-Matary, Y. S., Patnana, P. K., Zeller, A. C., Heuser, M., Thol, F. R., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.167288 · Cited by 28
“These mice harbor a transcriptional stop codon flanked by loxP sites upstream of a mutated Kras allele and, after removal of the stop codon, develop myeloproliferative disorder.(35) We crossed these mice with Gfi1bMxCre or Gfi1bMxCre mice, and after poly(I:C) administration, we observed mice for the emergence of disea…”
BackgroundEngineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?
Beurlet, S., Chomienne, C., & Padua, R. A. (2012) · Haematologica · doi:10.3324/haematol.2012.069385 · Cited by 25
Caraffini, V., Geiger, O., Rosenberger, A., Hatzl, S., Perfler, B., Berg, J. L., Lim, C. X., Strobl, H., Kashofer, K., Schauer, S., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.209650 · Cited by 23
Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?
Itzykson, R., Fenaux, P., & Solary, É. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.09.006 · Cited by 24
“Knock-in of Kras– and Nras–mutated allele in mice recapitulates a MDS/MPN phenotype [51,52], with increased granulocytes and monocytes, probably triggered by constitutive ERK and STAT5 signaling, and hypersensitivity to GM-CSF and IL-3 [53].”
What a Fish Can Learn from a Mouse: Principles and Strategies for Modeling Human Cancer in Mice
Bailey, J. M., Creamer, B. A., & Hollingsworth, M. A. (2009) · Zebrafish · doi:10.1089/zeb.2009.0626 · Cited by 22
Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders
Kaushansky, K. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.09.005 · Cited by 31
“Loss of a Ras regulatory protein, RasGAP, or overexpression of an activated form of Ras, a key component of hematopoietic cytokine signaling, results in a murine myeloproliferative syndrome (68,69).”
BackgroundMolecular diagnosis of acute myeloid leukemia
Watt, C. D., & Bagg, A. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.85 · Cited by 22
He, S., Jing, C., & Look, A. T. (2017) · Methods in cell biology · doi:10.1016/bs.mcb.2016.11.013 · Cited by 23
Caspase-8 is essential for maintaining chromosomal stability and suppressing B-cell lymphomagenesis
Hakem, A., Ghamrasni, S. E., Maire, G., Lemmers, B., Karásková, J., Jurisicova, A., Sanchez, O. H., Squire, J. A., & Hakem, R. (2012) · Blood · doi:10.1182/blood-2011-07-367532 · Cited by 20
Intracellular signaling by the erythropoietin receptor
Lodish, H. F., Ghaffari, S., Socolovsky, M., Tong, W., & Zhang, J. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8698-6_10 · Cited by 20
“throid progenitors in the in vitro culture system [ 86 ].”
BackgroundRal Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras
Omidvar, N., Pearn, L., Burnett, A. K., & Darley, R. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.10.3966-3975.2006 · Cited by 22
“genic mice (12), implying that Ras also affects the development”
BackgroundGenua, C. D., Norfo, R., Rodríguez-Meira, A., Wen, W. X., Drissen, R., Booth, C. A. G., Povinelli, B. J., Repapi, E., Gray, N., Carrelha, J., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205351 · Cited by 19
“Finally, the Kras;Mx1-Cremouse model develops a fatal myeloproliferative neoplasm (MPN); however, these mice do not develop AML.(18,19) Collectively, these studies provide evidence that RAS mutations are secondary events in AML development and are not present within pre-leukemic HSC.”
BackgroundPLC-γ and PI3K Link Cytokines to ERK Activation in Hematopoietic Cells with Normal and OncogenicKras
Díaz-Flores, E., Goldschmidt, H. L., Depeille, P., Ng, V., Akutagawa, J., Krisman, K., Crone, M., Burgess, M. R., Williams, O., Houseman, B. T., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004125 · Cited by 23
“These mice express oncogenic Kras G12D from its endogenous locus in hematopoietic cells and develop a fatal MPN that recapitulates many features of CMML and JMML ( 10 – 12 ).”
Sjogren, A.-K. M., Andersson, K., Khan, O. M., Olofsson, F. J., Karlsson, C., & Bergö, M. O. (2010) · Leukemia · doi:10.1038/leu.2010.242 · Cited by 16
Genetic Analyses of the Role of RCE1 in RAS Membrane Association and Transformation
Bergö, M. O., Wahlstrom, A. M., Fong, L. G., & Young, S. G. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)38026-9 · Cited by 16
RAS Pathway Mutations in Juvenile Myelomonocytic Leukemia
Emanuel, P. D. (2008) · Acta Haematologica · doi:10.1159/000140632 · Cited by 16
“An analogous approach has expressed Cre off of the interferon-inducible Mx1 promoter. These conditional knock-out approaches have also confirmed that inactivation of Nf1 leads to the development of myeloproliferative features.The above described Mx1-Cre technology has also been applied to conditionally express oncogen…”
MethodWang, J., Liu, Y., Tan, L. X., Lo, J. C., Du, J., Ryu, M., Ranheim, E. A., & Zhang, J. (2011) · Cell Cycle · doi:10.4161/cc.10.17.17195 · Cited by 16
“They quickly become dominant in bone marrow and drive MPD development, as described in the case of oncogenic Kras.(3)”
BackgroundInfluentialKobayashi, E. H., Shimizu, R., Kikuchi, Y., Takahashi, S., & Yamamoto, M. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030726 · Cited by 16
Tarnawsky, S. P., Chan, R. J., & Yöder, M. C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94031 · Cited by 16
“The Mx1Cre KrasG12D mouse was the first conditional animal model of JMML and continues to be studied extensively (12, 13).”
BackgroundPassioura, T., Shen, S., Symonds, G. P., & Dolnikov, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208877 · Cited by 15
“The expression of mutant ras genes in murine HSC/HPCs induces myeloid malignancies with long latency, suggesting that additional mutations (which presumably inactivate tumor-suppressive pathways) are required for leukemogenesis (MacKenzie et al., 1999; Chan et al., 2004).”
BackgroundAcute sensitivity of the oral mucosa to oncogenic K‐ras
van der Weyden, L., Alcolea, M. P., Jones, P. H., Rust, A. G., Arends, M. J., & Adams, D. J. (2011) · The Journal of Pathology · doi:10.1002/path.2853 · Cited by 14
Role of PTPN11 (SHP2) in Cancer
Chan, G., & Neel, B. G. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3649-6_4 · Cited by 14
Cbfβ Reduces Cbfβ-SMMHC–Associated Acute Myeloid Leukemia in Mice
Heilman, S. A., Kuo, Y., Goudswaard, C. S., Valk, P. J. M., & Castilla, L. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0959 · Cited by 14
Pati, H., & Veetil, K. K. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01084-y · Cited by 12
Oßwald, L., Hamarsheh, S., Uhl, F. M., Andrieux, G., Klein, C., Dierks, C., Duquesne, S., Braun, L. M., Schmitt-Graeff, A. H., Duyster, J., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0275 · Cited by 12
“In mice, conditional expression of oncogenic Kras from its endogenous promoter induces a myeloproliferative disease resembling human CMML and JMML (18, 19).”
BackgroundGerminal Center B-Cells Resist Transformation by Kras Independently of Tumor Suppressor Arf
Mullins, C. D., Su, M. Y., Hucthagowder, V., Chu, L., Lu, L., Kulkarni, S., Novack, D. V., Vij, R., & Tomasson, M. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067941 · Cited by 12
“In fact, T-cell lymphomas and lung adenomas have been described in Kras mice with Cre expressed via adenovirus and Mx-1 respectively [14,15,26].”
BackgroundMethodTanaka, H., Tamura, A., Sekai, M., Hamazaki, Y., & Minato, N. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01850.x · Cited by 15
SnapShot: Genetic Mouse Models of Cancer
Zender, L., Zuber, J. A., & Lowe, S. W. (2007) · Cell · doi:10.1016/j.cell.2007.05.013 · Cited by 11
Mouse models as tools to understand and study BCR-ABL1 diseases.
Koschmieder, S., & Schemionek, M. (2011) · PubMed · Cited by 12
Shen, S., Passioura, T., Symonds, G. P., & Dolnikov, A. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.02.011 · Cited by 12
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
Fontana, D., Gambacorti-Passerini, C. B., & Piazza, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756348 · Cited by 11
Zhang, J., Ranheim, E. A., Du, J., Liu, Y., Wang, J., Kong, G., & Zhang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.653154 · Cited by 8
Wehbe, Z., Ghanjati, F., & Flotho, C. (2021) · Cells · doi:10.3390/cells10092335 · Cited by 8
“Other Cells 2021, 10, 2335 3 of 17 models used knock-in strategies to manipulate the Ptpn11 [45,46] or Kras [47,48] genes.”
MethodInfluentialGeissler, K. H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751668 · Cited by 9
“Nras G12D C57BL/6 Conditional Monocytosis, granulocytosis, Wang (40) activation splenomegaly spontaneous CFU-GM growth Nras G12D C57Bl/6 Conditional Leukocytosis, splenomegaly Li (41) activation spontaneous CFU-GM growth Nras G12D BALB/c Transgenic Granulocytosis, monocytosis, mastocytosis Parikh (42) activation splen…”
BackgroundInfluentialChang, Y. I., Kong, G., Ranheim, E. A., Tu, P. S., Yu, Y., & Zhang, J. (2017) · PubMed · Cited by 8
PROGNOSTIC SIGNIFICANCE OF NRAS GENE MUTATIONS IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA
Aly, R., El-sharnoby, M. R., & Hagag, A. A. E. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.055 · Cited by 8
Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research
Bubnova, X., Hope, L., & Wheadon, H. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101318 · Cited by 8
“Further, transgenic mice expressing oncogenic K-RAS developed MPD [209], with AML only observed in K-RAS mutated mice whereby NF1 , a RAS inhibitor, was deficient [210].”
Epigenetic instability at imprinting control regions in a KrasG12D-induced T-cell neoplasm
Bretz, C. L., Langohr, I. M., Lee, S., & Kim, J. (2015) · Epigenetics · doi:10.1080/15592294.2015.1110672 · Cited by 7
“This is consistent with observations from previous studies of LSLKras mice.(19) The squamous papillomas caused discomfort for the animals such that they experienced difficulties eating and defecating to a point that the animals of the KPM and KM cohorts often experienced significant weight loss (15% of body weight) by…”
BackgroundResultKamata, T., Dankort, D. L., Kang, J., Giblett, S. M., Pritchard, C. A., McMahon, M., & Leavitt, A. D. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0294 · Cited by 7
Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis
Karra, L., Romero–Moya, D., Ksionda, O., Krush, M., Gu, Z., Mues, M., Depeille, P., Mullighan, C. G., & Roose, J. P. (2020) · Oncogene · doi:10.1038/s41388-020-01469-8 · Cited by 8
“Such skin papillomas are also reported in the KrasMx1CRE model [10].”
BackgroundHematopoietic-restricted Ptpn11E76K reveals indolent MPN progression in mice
Tarnawsky, S. P., Yu, W., Qu, C., Chan, R. J., & Yöder, M. C. (2018) · Oncotarget · doi:10.18632/oncotarget.25073 · Cited by 7
Baker, S. J., Cosenza, S. C., Reddy, M. V. R., & Reddy, E. P. (2019) · Oncotarget · doi:10.18632/oncotarget.26735 · Cited by 7
“Extramedullary hematopoiesis often occurs in myeloproliferative disorders and is recapitulated in the Mx1cre-Kas+/G12D model [14, 15].”
BackgroundBelotserkovskaya, E., & Demidov, O. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111510 · Cited by 7
“Secondary AML is the main cause of lethal outcomes in CMML patients [10].”
BackgroundInfluentialMouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia
Mohanty, S., & Heuser, M. (2021) · Cancers · doi:10.3390/cancers13246192 · Cited by 6
“KRAS KRAS G12D-ND [38] KRAS G12DMPN [39,40] Kras−/− -Embryonic lethal [41,42]”
Background
Metadata
- Authors
- Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Emory University (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Exelixis (United States) (US)
- Abramson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Gilliland, D. Gary
- Venue
- Journal of Clinical Investigation
- Published
- 2004-02-15
- Volume
- 113
- Issue
- 4
- Pages
- 528-538
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC338267
- OpenAlex
- W2147839086
- Cited by
- 270
- References
- 73
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 8 · 2017: 12 · 2016: 9 · 2015: 10 · 2014: 13 · 2013: 16 · 2012: 12
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Leukemia and Lymphoma Society
- National Institutes of Health (CA66996)
- National Cancer Institute (#CA66996, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK51564)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- oncogenic KRAS, endogenous promoter, conditional alleles, Cre-mediated recombination, myeloproliferative neoplasms, acute myeloid leukemia, hematopoietic system, myeloid hyperplasia, extramedullary hematopoiesis, cooperating mutations, RAS inhibitors, gene dosage
- MeSH terms
- Adenoma, Alleles, Animals, Bone Marrow Cells, Cells, Cultured, Hematopoietic Stem Cells, Humans, Mice, Inbred Strains, Mice, Transgenic, Myeloproliferative Disorders, Neoplasms, Papilloma, Phenotype, Promoter Regions, Genetic, Genes, ras, Leukemia, Myeloid, Acute, Gene Expression Regulation, Neoplastic, Bone Marrow Transplantation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.